Although Chinese biopharmaceutical companies currently mainly focus on out-licensing their therapeutic products, it remains difficult to obtain details on their preclinical pipeline products
China preclinical pipelines - Oncology (published May 2024)
Our China preclinical pipelines – Oncology report provides new opportunities to quickly screen potential preclinical oncology products from China for in-licensing, investments and competitor information. The report provides insight into 425 preclinical oncology products stemming from China identified between January and March of 2024. At the moment of screening all identified products were unpartnered outside of China. China preclinical pipelines – Oncology covers 168 targets for both hematological malignancies and solid tumors divided over monoclonal antibodies, bispecific antibodies, trispecific antibodies, (bispecific) antibody drug conjugates, cell therapy, proteins/peptides, PROTACs, radiopharmaceuticals and small molecules. The report also contains short company profiles on 139 Chinese private and public companies with homepage link and information on ownership, investors, therapeutic areas, molecule types, proprietary technologies, current strategic alliance partners and preclinical oncology pipeline products covered in this report
Targets covered in report: 4-1BB, 5T4, ALK-1, AMHR2, ANG2, AR-V7, ATM, ATR, Aurora B, AXL, B7-H3, B7-H4, BCL-2, BCL-6, BCL-XL, BCMA, BCR-ABL, BET, BKR, BRAF, BTK, BTN3A1, CAF, CBP/p300, CCR8, CD3, CD7, CD8, CD16a, CD19, CD20, CD24, CD25, CD28, CD36, CD38, CD39, CD40, CD47, CD55, CD73, CD98, CD200R1, CD228, CDK12/12, CDK4/6, CDK7, CDK8, CEACAM1, CEACAM5/CEACAM6, CLDN6, CLDN18.2, CLL1, c-Met, c-Myc, CRBN E3, CTLA-4, DGKA, DHODH, DLL3, EGFR, ENPP1, EphA2, ER-α, ETa, FAK, FBXW7 E3, FGFR2, FGFR3, FLT3, FOLR1, Gasdermin, GCC, GLS1, GPC3, GPRC5D, GRPR, GSPT1, HER2, HER3, HIF-2α, IDH1/2, IL-2, IL-8 IL-12, IL-13, IL-15, integrin αvβ8, IRAK4, KIF18A, KIR3DL2, KLRG1, KRAS G12C/D/V, LAG3, LIFR, LILRB1, LILRB2, LILRB4, LIV-1, LY6G6D, MAGE A1, MAT2A, MDM2, Menin-MLL, MKLP2, MSLN, MUC1, MUC17, NaPi2b, Nectin-4, NKG2A, NKG2C, NKP30, NKp46, NKRT, OX40, p53, PAK4, PARP1, PARP7, PD-1, PD-L1, PI3Kα, PKMYT-1, pMEK, Polθ, PRMT5, PSGL-1, PSMA, PTK7, PVRIG, RAS, RET, ROR1, SEMA4D, SHP2, Siglec-7/9, Siglec-15, SIRT6, SKP2, MARCA2, SIRPα, SOS1, STAT3, STEAP1, STING, STTR2, TEAD, TGFß, TIGIT, TIM-3, TLR8, TNFR2, TOPO1, TREM2, TROP-2, USP1, VEGF, VSIG4, WDR5, WEE1, Wnt/ß-catenin, WRN, WT1
Report format: PDF
Pages: 300
Prices:
- complete report : upon request
- antibodies section (207 preclinical products): upon request
- small molecules and PROTACs section (176 preclinical products): upon request
Contact us for more information or to request a sample